Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles
France is facing various reforms to its health care system as a direct result of the scandal involving Servier’s diabetes drug Mediator (benfluorex), which may have caused up to 500 deaths.
You may also be interested in...
France will eliminate industry seat on the nation's HTA transparency panel, in apparent continuing Mediator fall-out.
Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.
Bayer‘s Chairman Marijn Dekkers says the pharma sector’s poor public reputation and consequent loss of faith in the industry risks destroying the European drug business model.